Condition: Metastatic Prostate Cancer · Sponsor: AstraZeneca
The main purpose of this study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer agents for treatment of metastatic prostate cancer.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Fayetteville, Arkansas, United States | Recruiting |
| Research Site | Los Angeles, California, United States | Recruiting |
| Research Site | Towson, Maryland, United States | Suspended |
| Research Site | Boston, Massachusetts, United States | Recruiting |
| Research Site | Ann Arbor, Michigan, United States | Recruiting |
| Research Site | Detroit, Michigan, United States | Recruiting |
| Research Site | Buffalo, New York, United States | Suspended |
| Research Site | New York, New York, United States | Recruiting |
| Research Site | Providence, Rhode Island, United States | Recruiting |
| Research Site | Myrtle Beach, South Carolina, United States | Recruiting |
| Research Site | Houston, Texas, United States | Recruiting |
| Research Site | Barretos, Brazil | Not Yet Recruiting |
+ 40 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07181161